PAREXEL Opens North American Facilities in PA
PAREXEL recently opened a state-of-the-art North American Coordination Hub and Distribution Center in Pennsylvania-marking an expanded presence in the region. The facility, located in Quakertown, will provide customers around the world with clinical trial supplies and logistics services designed to reduce study start-up planning and accelerate first patient-in. The North American Coordination Hub and Distribution Center can:
- Provide-local and/or central sourcing of comparator and non-investigational medicinal products
- Coordinate investigational medicinal products manufacturing through contract manufacturing organization or sponsor-delegated partners to optimize material utilization, supply and re-supply strategies, expiration dates and costs
- Offer full-service and secondary clinical packaging for randomized, double-blind or two/three panel studies, as well as customized packaging design, custom secondary packaging and patient supply kits
- Develop, translate and distribute all the documentation for sites, investigators or patients
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
